COVID-19 has created significant challenges for the Venture Capital (VC) market and life science companies seeking funding during the pandemic. While the pandemic has undoubtedly added a new layer of risk to an inherently risky field, the fundamentals for what makes a company attractive to a VC have remained steady.
Ken Malone is a co-founder of Early Charm Ventures, a venture studio founded in 2012 in Baltimore (Charm City) that converts science to business. Early Charm specializes in taking brilliant scientific discoveries made at universities and turning them into companies focused on growth. They don’t chase quick exits. They build companies that create sustainable value.
Raising Capital During a Pandemic: Strong Networks and Respected Advocates Remain Critical to Fundraising Efforts Talk to any experienced venture capital investor and they’ll tell you that personal, face-to-face interactions [….]
VCs Cautious of “COVID-19 Contortionists” and Telemedicine “Gold Rush” COVID-19 is fundamentally changing how we live, how we do business, and how we approach and deliver our healthcare. In the [….]
Four Leading VC’s Give Advice on Raising Capital During COVID-19 Six Key Takeaways for Entrepreneurs and Startups on Fundraising and How Investors View the Post-Coronavirus Landscape Over 200 entrepreneurs, startup [….]
I know what you’re thinking…it’s hard enough to raise venture capital for life science/healthcare startups in normal times, but throw a global pandemic and economic meltdown into the mix and [….]
BioHealth Capital Region Startups Raised More Than $739M in 2019 These 15 Biohealth Startups had a Banner Year, Setting Themselves Up for Success in 2020 The startup ecosystem in the [….]
Five Female Investors Who Are Making Their Mark in Life Science November 26, 2019 Less than 10% of decision-makers at U.S. venture capital (VC) firms are women and a whopping [….]
If You Want to Raise Venture Capital These are Two Often Overlooked Factors That Investors Want to See November 12, 2019 If you are an entrepreneur, there is no better [….]